These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34489945)

  • 1. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
    Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
    Front Immunol; 2021; 12():698312. PubMed ID: 34489945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.
    Gupta P; Suman S; Mishra M; Mishra S; Srivastava N; Kumar V; Singh PK; Shukla Y
    Proteomics Clin Appl; 2016 May; 10(5):564-73. PubMed ID: 27068564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
    Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
    Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer.
    Duan Y; Cui C; Qiu C; Sun G; Wang X; Wang P; Ye H; Dai L; Shi J
    Dis Markers; 2022; 2022():6657820. PubMed ID: 35273656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
    Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
    Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
    Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.
    Wang T; Liu H; Pei L; Wang K; Song C; Wang P; Ye H; Zhang J; Ji Z; Ouyang S; Dai L
    Clin Immunol; 2020 Jan; 210():108262. PubMed ID: 31629809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
    Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
    Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
    Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
    Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
    Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 18. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Young Han C; Bedia JS; Yang WL; Hawley SJ; Bergan L; Hopper M; Celestino J; Guo J; Gornet TG; Soosaipillai A; Yang H; Doskocil SD; Lokshin AE; Handy BC; Diamandis EP; Moore RG; Lu KH; Lu Z; Anderson KS; Drescher CW; Skates SJ; Bast RC
    Br J Cancer; 2024 Mar; 130(5):861-868. PubMed ID: 38195887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.